G1G Stock Overview
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Zelira Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.42 |
| 52 Week High | AU$1.79 |
| 52 Week Low | AU$0.40 |
| Beta | 0.52 |
| 1 Month Change | 3.92% |
| 3 Month Change | -17.67% |
| 1 Year Change | -22.20% |
| 3 Year Change | -92.06% |
| 5 Year Change | -89.90% |
| Change since IPO | -93.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| G1G | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 3.9% | 1.9% | 1.2% |
| 1Y | -22.2% | -28.2% | 2.0% |
Return vs Industry: G1G exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: G1G underperformed the German Market which returned 2% over the past year.
Price Volatility
| G1G volatility | |
|---|---|
| G1G Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: G1G's share price has been volatile over the past 3 months.
Volatility Over Time: G1G's weekly volatility has decreased from 32% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Oludare Odumosu | zeliratx.com |
Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. The company offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. It also provides over the counter products, including SprinJene, an oral care product; and RAF FIVE, a dermatology product, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology.
Zelira Therapeutics Limited Fundamentals Summary
| G1G fundamental statistics | |
|---|---|
| Market cap | €4.97m |
| Earnings (TTM) | -€22.32m |
| Revenue (TTM) | €170.85k |
29.1x
P/S Ratio-0.2x
P/E RatioIs G1G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G1G income statement (TTM) | |
|---|---|
| Revenue | AU$278.90k |
| Cost of Revenue | AU$358.24k |
| Gross Profit | -AU$79.34k |
| Other Expenses | AU$36.35m |
| Earnings | -AU$36.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.21 |
| Gross Margin | -28.45% |
| Net Profit Margin | -13,062.44% |
| Debt/Equity Ratio | -68.8% |
How did G1G perform over the long term?
See historical performance and comparison